Clearmind Medicine Inc. (CMND) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Vancouver, BC, Canada. Le PDG actuel est Adi Zuloff-Shani.
CMND a date d'introduction en bourse 2022-11-15, 4 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $88.83K.
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
